1 Evaluation of the current therapeutic approaches for

2 **COVID-19: a meta-analysis**

- ³ Zeinab Abdelrahman, MS^{1,2}, Qian Liu, BS^{1,2}, Shanmei Jiang, BS^{1,2}, Mengyuan Li,
- 4 MS^{1,2}, Yue Zhang, Ph.D.^{3,4,5}, Xiaosheng Wang, Ph.D.^{1,2*}
- ¹ Biomedical Informatics Research Lab, School of Basic Medicine and Clinical
- 6 Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
- ² Big Data Research Institute, China Pharmaceutical University, Nanjing 211198,
- 8 China
- ³ Pinghu Hospital of Shenzhen University, Shenzhen 440307, China
- ⁴ Futian Hospital for Rheumatic Diseases, Shenzhen 518000, China
- ⁵ Department of Rheumatology and Immunology, The First Clinical College of Harbin
- 12 Medical University, Harbin 150001, China
- 13 Authors emails
- 14 Zeinab Abdelrahman (zeinabmohamed86@yahoo.com)
- 15 Qian Liu (3319091437@stu.cpu.edu.cn)
- 16 Shanmei Jiang (shanmei.jiang@stu.cpu.edu.cn)
- 17 Mengyuan Li (limengyuan_cpu@163.com)
- 18 Yue Zhang (zy1001@yahoo.com)
- 19 * Correspondence to Xiaosheng Wang, MD, PhD
- 20 Director, Biomedical Informatics Research Lab
- 21 Associate Professor, School of Basic Medicine and Clinical Pharmacy
- 22 China Pharmaceutical University

- 23 Address: No. 639 Longmian Avenue, Jiangning District, Nanjing 211198, Jiangsu,
- 24 China
- 25 E-mail: xiaosheng.wang@cpu.edu.cn; Tel: +86-186-0129-9809
- 26 Funding
- 27 This work was supported by the China Pharmaceutical University (grant number
- 28 3150120001 to Xiaosheng Wang).
- 29 Running title
- 30 Evaluation of therapeutic approaches for COVID-19
- 31 Word count
- Abstract: 241, Main manuscript: 2380, Tables and Figures: 5, Supplemental contents:
- 33 13
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- ...
- 41
- 42
- 43
- 44

45 Abstract

46	Background and rationale: Limited data on the efficacy and safety of currently
47	applied COVID-19 therapeutics and their impact on COVID-19 outcomes have raised
48	additional concern. Aim and Methods: We estimated the impact of the current
49	treatments on the efficacy and safety of COVID-19 by a meta-analysis. The
50	comprehensive search included studies reporting clinical features and treatment
51	strategies published from January 21, 2020, to May 15, 2020. Results: We included
52	52 studies that involved 13,966 COVID-19 patients. We found that the most prevalent
53	treatments were antivirals (proportion: 0.74, 95% CI ¹ : [0.65, 0.83]) and antibiotics
54	(proportion: 0.73, 95% CI: [0.62, 0.83]). The COVID-19 severity increased among
55	patients taking glucocorticoids (risk ratio (RR) 2 = 1.71, 95% CI: [1.06, 2.76]) or
56	immunoglobulins (RR = 3.83, 95% CI: [1.27, 11.53]), and renal replacement therapy
57	(RRT) and glucocorticoids increased the length of ICU stay (RRT 3 : RR \square = 11.89, 95%
58	CI: [3.26, 43.39]; glucocorticoids: RR = 3.10, 95% CI: [1.52, 6.29]). The COVID-19
59	severity and mortality increased among patients taking tocilizumab (severity: F =
60	25.53, $P = 0.02$; mortality: $F^4 = 19.37$, $P = 0.02$). The most effective treatment was
61	the combination of arbidol with lopinavir/ritonavir compared with placebo (mean
62	difference = 0.5, 95% CI [-0.60, 1.66]), and the safest combination was remdesivir
63	and lopinavir/ritonavir (RR= 0.78, 95% CI [0.32, 1.91]). Conclusion: glucocorticoids,
64	immunoglobulins, RRT, and tocilizumab might worsen COVID-19 outcomes, and the

¹ CI: confidence interval

² RR: risk ratio

³ RRT: renal replacement therapy

⁴ F: F-test

65	most effective and safest treatment strategy for COVID-19 is the combination of
66	different antivirals.
67	
68	Keywords: COVID-19 drug treatment; COVID-19; Antiviral Agents; Interferons;
69	Hydroxychloroquine; tocilizumab
70	
71	
72	
73	
74	
75	
76	
77	
78	
79	
80	
81	
82	
83	
84	
85	
86	1. Introduction

87	Since the outbreak of the coronavirus disease 2019 (COVID-19) caused by severe
88	acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in December 2019, more
89	than 14 million cases and 613,879 deaths have been reported as of July 22, 2020, in
90	the world ^[1] . Compared to other beta coronaviruses that have caused epidemics over
91	the last two decades, including severe acute respiratory syndrome coronavirus
92	(SARS-CoV) ^[2] and Middle East respiratory syndrome coronavirus (MERS-CoV) ^[3] ,
93	SARS-CoV-2 exhibits higher infectivity while lower fatality that makes it more
94	destructive ^[4] . The rapid development of effective treatment approaches for
95	COVID-19 is urgently needed since there is no specific therapy or vaccine for
96	COVID-19 currently. Previous experiences from SARS and MERS treatment suggest
97	that several interventions, including antivirals, such as lopinavir/ritonavir and
98	umifenovir, glucocorticoids, interferons, ribavirin, besides newly introduced drugs
99	such as chloroquine or its derivative hydroxychloroquine, and convalescent plasma,
100	may improve clinical outcomes in COVID-19 patients, whereas the related data are
101	not conclusive. Since the evidence of the effectiveness of these treatments remains
102	lacking, we conducted a meta-analysis of the therapeutic approaches for COVID-19.
103	This meta-analysis aimed to identify favorable and unfavorable treatment strategies
104	for COVID-19 by comparing different treatment approaches using machine learning
105	models.

First, we conducted a proportional meta-analysis to summarize the pooled effect of the weighted proportion of each treatment. Next, we identified the impact of each treatment on the severity and mortality of COVID-19. Finally, we conducted the

network meta-analysis to, directly and indirectly, compare different treatment strategies. We summarized available randomized and non-randomized clinical trials of several treatment strategies and provided point estimates and their 95% confidence intervals (CIs) for the associations between these treatment strategies and given endpoints.

114 *2. Methods*

115 2.1 Search strategy and selection criteria

116 We searched for publications between January 21, 2020, and May 15, 2020, in 117 databases of PubMed, EMBASE, CNKI, Wanfang, Cochrane library, 118 ClinicalTrails.gov, Scopus, Lancet, N Engl J Med and JAMA platforms, and Web of 119 Science. We used the EndNote X9.0 software to exclude duplicate or irrelevant articles. We used the search term "2019 novel coronavirus, COVID-19 and 120 121 SARS-CoV-2" AND "treatment, clinical characteristics, epidemiological 122 characteristics, clinical trials, cohort studies, observational studies, case series" 123 without language and age restriction. To identify missed studies, we checked the 124 reference list for each selected paper. Our meta-analysis included publications 125 involving the following information: clinical features, laboratory findings, and 126 treatment approaches for COVID-19 patients with clinically defined severity or 127 mortality. We excluded the following studies: duplicate publications, preprints, 128 reviews, case reports, family-based studies, unrelated titles or abstracts, studies not 129 involving clinical features, laboratory findings, treatment approaches, and animal or 130 in vitro studies. The literature search steps followed the transparent reporting of

131 systematic reviews and meta-analyses "PRISMA" (Figure 1, Supplemental Content132 1).

133 2.2 Data extraction

134 Two investigators (QL and SJ) performed a literature search and data extraction, and 135 another investigator (ZA) resolved the disagreements. We extracted the following 136 variables: author, date, age, gender, number of participants in different groups for comparisons, including severe versus non-severe, ICU versus non-ICU, death versus 137 138 survival, and deterioration versus discharge. The extracted data included publication 139 date, country, study design, number of enrolled subjects, data collection method, 140 baseline characteristics before treatment, diagnostic method, population, treatment 141 details, time from admission to starting treatment, and outcomes in patients.

142

143 **2.3 Data analyses**

144 We conducted a proportional meta-analysis to account for the weighted average 145 proportion of each treatment. We also conducted the subgroup meta-analysis to 146 identify the impact of each treatment on the disease severity, such as the utility of antibiotics or antivirals in severe versus non-severe, ICU versus non-ICU, death 147 148 versus survival, and deterioration versus discharge patients. Besides, we conducted 149 the network meta-analysis to account for the relationship between clinical outcomes 150 and borrowed strength across studies. We defined the disease severity as a 151 dichotomous variable. We normalized the data by double-arcsine- or 152 logit-transformation and confirmed their normal distribution by the Shapiro-Wilk test

153	before meta-analyses. We assessed statistical heterogeneity using the I^2 statistic and			
154	Cochran's Q test with a threshold of $I^2 > 50\%$ or $P \le 0.05$. We adopted a			
155	random-effect model in terms of statistical heterogeneity. We performed the			
156	meta-analysis using R software and Cochrane software REVMAN 5 ^[5] . For the			
157	proportional meta-analysis, we used the R package "metafor" and "meta" [6] based			
158	on the restricted maximum likelihood method. We estimated the summary			
159	proportional effect size as the weighted average of the observed effect sizes in			
160	individual studies.			

For subgroup meta-analysis, we applied random models and mixed-effect 161 meta-regression for different outcomes. The subgroups were defined by different 162 163 severity definition terms in the studies. We used the random-effect model in the 164 subgroup meta-analysis, and in the meta-regression, we used the mixed-effect model 165 with the risk ratio (RR) as the estimated effect size to evaluate the impact of different 166 drugs on the disease severity. We also conducted the network meta-analysis of 10 167 different drugs in 13 studies to estimate if one intervention is more or less effective 168 than another intervention for COVID-19 patients. In the network meta-analysis, we used a random-effect model with the RR as the size effect and estimated the network 169 170 inconsistency.

171

172 2.4 Study selection and risk of bias assessment

We assessed the risk of bias eligible observational studies, such as cross-sectional, cohort studies, and case series, following the Strengthening the Reporting of

175	Observational Studies in Epidemiology (STROBE) reporting guidelines ^[7] . We
176	assessed the risk of bias in randomized control trials using the Cochrane risk-of-bias
177	tool for randomized trials (ROB-2) ^[8] . We conducted both risks of bias evaluations by
178	the two investigators (QL and SJ) independently, each assigned an overall risk of bias
179	to each eligible study, and consulted a third reviewer (ZA) if they disagreed. We
180	summarized the results in Supplemental Content 6.
181	
182	3. Results
183	We initially identified 2,221 articles based on our search criteria, most of which were
183 184	We initially identified 2,221 articles based on our search criteria, most of which were irrelevant to our research objective or without published results (Figure 1). Finally, we

186 ^{35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60]} in our meta-analysis,

187 which involved a total of 13,966 subjects. A summary of these studies is presented in

188 Supplemental Content 2.

189 3.1 Proportional meta-analysis

We performed proportional meta-analyses to estimate one-dimensional binomial (weighted) average proportions. We obtained the average of the proportions of multiple studies weighted by the inverse of their sampling variances using the random-effect model. We defined eight groups of treatments commonly used against COVID-19, as shown in Supplemental Content 3. The sample sizes in these studies ranged from 9 to 5,700, with a total number of 13,966. The treatment categories included antibiotics, antivirals, glucocorticoids, chloroquine or hydroxychloroquine,

immunoglobulin, interferons, tocilizumab, and renal replacement therapy (RRT). The
random-effect model estimated the prevalence of each treatment and found that the
highest prevalence were antivirals (proportion: 0.74, 95% CI: [0.65, 0.83]) and
antibiotics (proportion: 0.73, 95% CI: [0.62, 0.83]) (Figure 2). We showed the results
of proportional meta-analysis heterogeneity in Supplemental Content 4.

202 To estimate the association between treatment and disease severity, we performed a subgroup meta-analysis or meta-regression to quantify each drug's effect on the 203 204 severity of COVID-19. This analysis would elucidate whether a treatment can reduce 205 COVID-19 risk or not. The severity terms included "severe" versus "non-severe," "death" versus "survival," "deterioration," versus "discharge," and "ICU" versus 206 207 "non-ICU." We performed a subgroup meta-analysis on 42 studies. We also conducted 208 meta-regression for chloroquine or hydroxychloroquine and tocilizumab for which we 209 had no sufficient data to perform subgroup meta-analysis. We used the general term 210 "relative risk (RR)" to uniformly refer to the different severity terms. The results 211 showed that the risk of COVID-19 severity increased among patients taking 212 glucocorticoids (RR = 1.71, 95% CI: [1.06, 2.76]) or immunoglobulins (RR = 3.83, 95% CI: [1.27, 11.53]), and RRT and glucocorticoids increased the length in ICU 213 214 among COVID-19 patients (RRT: $RR \square = 11.89, 95\%$ CI: [3.26, 43.39]; 215 glucocorticoids: RR = 3.10, 95% CI: [1.52, 6.29]). In addition, meta-regression 216 analysis showed that the COVID-19 severity and mortality increased among patients 217 taking tocilizumab (severity: F = 25.53, P = 0.02; mortality: F = 19.37, P = 0.02), but 218 there were no significant differences among patients taking chloroquine or

hydroxychloroquine. The pooled RR of eight treatments indicated that the use of
glucocorticoids, immunoglobulin, tocilizumab, and RRT were likely to increase
COVID-19 progression and severity (Table 1 and Supplemental Content 7 and 8).

222 To determine if there are outliers that could influence our analysis results, we 223 performed leave-one-out (LOO) analyses. In brief, each study was removed once, and 224 the summary proportion was re-estimated based on the remaining studies. Studies 225 with a statistically significant impact on the fitted model were removed as outliers, 226 and the model was re-fitted again. Among the eight models, we found that only in RRT, interferon, and tocilizumab models, the studies ^[54, 32, 28] had a significant impact, 227 228 with Z values of 3.5, 4.5, and -5.2, respectively, and the heterogeneity reduction to 229 75.9%, 96.8%, and 88%, respectively (Supplemental Content 9 and 10). Finally, we 230 assessed the potential publication bias in each treatment model using a funnel plot of 231 the mixed-effect meta-regression model and the Egger's regression test with the 232 standard error as a predictor. We observed that the funnel plots were roughly 233 symmetrical and that the Egger's test was significant in four treatment models 234 (antibiotics, antivirals, immunoglobulin, and RRT), indicating the clear evidence of 235 publication bias (Supplemental Content 11).

236

237 3.2 Network meta-analysis

To compare the effect of different anti-COVID-19 treatment approaches, we
performed network meta-analysis. We included only 13 studies ^[38, 32, 26, 24, 22, 23, 28, 60, 30, 27, 21, 29, 25] in the analysis because of network inconsistency (Supplemental Content 5).

241	First, we used the frequentist network model to define the effect size of each
242	comparison as the mean difference (MD) and the source of network heterogeneity as
243	the Q value. We observed the highest Q value ($Q = 21.02$) in the study by Tang et al.
244	^[23] , and its network inconsistency was as high as 93.7%. Next, we estimated the effect
245	of the treatments relative to the placebo, which was supplemental oxygen,
246	noninvasive and invasive ventilation, antibiotics, vasopressor support, RRT, or
247	extracorporeal membrane oxygenation (ECMO) (Figure 3). Many studies ^{[38, 26,22, 30, 21,}
248	^{60]} have performed a comparison between lopinavir/ritonavir or remdesvir and placebo.
249	The best improvement in the effect was the combination of arbidol with lopinavir or
250	ritonavir (MD = 0.5 , 95% CI [-0.60, 1.66]), and the next one was hydroxychloroquine
251	(MD = 0.3, 95% CI [-0.15, 0.68]) when compared to placebo. We also estimated the
252	percentage of direct and indirect evidence used for each comparison, which may
253	contribute to the assumption of consistency underlying the network meta-analysis
254	model. Nevertheless, this estimate can evaluate the extent to which the comparisons
255	were inferred by direct or indirect evidence. We produced a matrix for the effect sizes
256	of all possible treatment combinations and found that the combination of remdesivir
257	and lopinavir/ritonavir had the lowest RR (RR = 0.78, 95%CI [0.32, 1.91]) (Figure 4).
258	To determine which COVID-19 treatment is the most effective, we ranked the
259	treatments based on the P score in the frequentist model (Supplemental Content 12).
260	We observed that arbidol plus lopinavir/ritonavir had the highest P score of 0.9995,
261	and lopinavir/ritonavir plus interferon had the second-highest P score of 0.851,
262	followed by chloroquine (P score = 0.579). These results indicate that the antiviral

treatment has the best effect against COVID-19 and that chloroquine and itsderivative are also effective.

Assessing the publication bias of a network meta-analysis in its aggregated form is problematic ^[61]. Thus, we conducted an analysis called "comparison-adjusted funnel plot" to assess the possible publication bias under an a priori hypothesis that specific mechanisms may cause the publication bias. We did not observe the funnel asymmetry (Egger's Test, P = 0.38) (Supplemental Content 13).

270

271 4. Discussion

272 Currently, most of the COVID-19 treatments are symptomatic treatments, and oxygen 273 therapy is the first step in addressing respiratory impairment. Accumulating 274 knowledge on the pathophysiology of lung damage provides clinicians the strategies for dealing with respiratory failure caused by COVID-19^[62]. Several treatment 275 276 attempts have become an essential part of COVID-19 treatment and management 277 protocol, such as antibiotics, antivirals, glucocorticoids, interferons, RRT, chloroquine 278 or hydroxychloroquine, and tocilizumab, whereas there were no recommendations or rationale for using them. Earlier, 58% of COVID-19 patients in Wuhan were treated 279 280 with antibiotics. Later on, the WHO recommended using empiric antibiotics to cover bacterial superinfections of COVID-19 patients ^[63]. The rationale for using 281 282 glucocorticoids is still controversial, although the most common reason for using 283 steroids is to mitigate the destructive inflammatory response in severe COVID-19 [64] 284 Several mechanisms patients have proposed that chloroquine or

285 hydroxychloroquine could be effective against SARS-CoV-2^[65]. However, the 286 clinical evidence regarding the effectiveness of these treatments remains lacking. Our 287 meta-analysis identified and summarized eight therapeutic approaches commonly 288 used in COVID-19 treatment, including antibiotics, antivirals, immunoglobulin, 289 glucocorticoids, interferons, chloroquine, or hydroxychloroquine, RRT, and 290 tocilizumab. First, we found that the use of antibiotics, antivirals, and chloroquine or hydroxychloroquine was the most prevalent. Second, we found that the use of 291 292 glucocorticoids, immunoglobulin, RRT, and tocilizumab was likely to promote the 293 disease severity and deterioration among COVID-19 patients. Third, we found that 294 the use of a combination of arbidol plus lopinavir/ritonavir had the best effect on 295 COVID-19 patients relative to placebo, while the use of umifenovir had the worst 296 effect. Finally, we confirmed that antivirals, especially lopinavir/ritonavir, were 297 superior to the other anti-COVID-19 treatments.

This meta-analysis has several limitations. First, we may not include some relevant studies due to certain restrictions in searching for some databases. Second, the quality of evidence is limited by data primarily derived from retrospective analyses, which included heterogeneous data reporting and study design. Third, the confidence of the results from this meta-analysis is limited by insufficient data of the randomized control trials.

In conclusion, glucocorticoids, immunoglobulins, RRT, and tocilizumab may worsen outcomes in COVID-19. The most effective and safest treatment strategy for COVID-19 is the combination of different antivirals, supporting the use of antivirals

307	as the basic treatment of COVID-19 with no association with disease progression and
308	mortality. Our data are potentially valuable for clinical treatment and management of
309	COVID-19 patients.
310	
311	
312	Funding
313	This work was supported by the China Pharmaceutical University (grant number
314	3150120001 to Xiaosheng Wang).
315	Declarations of interest
316	The authors declare that they have no known competing financial interests or personal
317	relationships that could have appeared to influence the work reported in this paper.
210	Author contribution
318 319	
319 320	Zeinab Abdelrahman: Conceptualization, Methodology, Software, Investigation,
319	
319 320	Zeinab Abdelrahman: Conceptualization, Methodology, Software, Investigation,
319 320 321	Zeinab Abdelrahman: Conceptualization, Methodology, Software, Investigation, Formal analysis, Writing - Original Draft, Visualization; Qing Liu: Investigation;
319 320 321 322	Zeinab Abdelrahman: Conceptualization, Methodology, Software, Investigation, Formal analysis, Writing - Original Draft, Visualization; Qing Liu: Investigation; Shanmei Jiang: Investigation; Mengyuan Li: Visualization; Yue Zhang:
 319 320 321 322 323 	Zeinab Abdelrahman: Conceptualization, Methodology, Software, Investigation, Formal analysis, Writing - Original Draft, Visualization; Qing Liu: Investigation; Shanmei Jiang: Investigation; Mengyuan Li: Visualization; Yue Zhang: Conceptualization; Xiaosheng Wang: Conceptualization, Methodology, Project
 319 320 321 322 323 324 	Zeinab Abdelrahman: Conceptualization, Methodology, Software, Investigation, Formal analysis, Writing - Original Draft, Visualization; Qing Liu: Investigation; Shanmei Jiang: Investigation; Mengyuan Li: Visualization; Yue Zhang: Conceptualization; Xiaosheng Wang: Conceptualization, Methodology, Project administration, Funding acquisition, Writing - Review & Editing, Supervision.
 319 320 321 322 323 324 325 	Zeinab Abdelrahman: Conceptualization, Methodology, Software, Investigation, Formal analysis, Writing - Original Draft, Visualization; Qing Liu: Investigation; Shanmei Jiang: Investigation; Mengyuan Li: Visualization; Yue Zhang: Conceptualization; Xiaosheng Wang: Conceptualization, Methodology, Project administration, Funding acquisition, Writing - Review & Editing, Supervision. Acknowledgments
 319 320 321 322 323 324 325 326 	Zeinab Abdelrahman: Conceptualization, Methodology, Software, Investigation, Formal analysis, Writing - Original Draft, Visualization; Qing Liu: Investigation; Shanmei Jiang: Investigation; Mengyuan Li: Visualization; Yue Zhang: Conceptualization; Xiaosheng Wang: Conceptualization, Methodology, Project administration, Funding acquisition, Writing - Review & Editing, Supervision. Acknowledgments
 319 320 321 322 323 324 325 326 327 	Zeinab Abdelrahman: Conceptualization, Methodology, Software, Investigation, Formal analysis, Writing - Original Draft, Visualization; Qing Liu: Investigation; Shanmei Jiang: Investigation; Mengyuan Li: Visualization; Yue Zhang: Conceptualization; Xiaosheng Wang: Conceptualization, Methodology, Project administration, Funding acquisition, Writing - Review & Editing, Supervision. Acknowledgments

331		
332		
333		
334		
335		
336	5. Re	eferences
337	[1]	University JH. coronavirus resource center.
338		https://coronavirus.jhu.edu/map.html.
339	[2]	Ksiazek TG, Erdman D, Goldsmith CS, et al. A novel coronavirus associated
340		with severe acute respiratory syndrome. N Engl J Med.
341		2003;348(20):1953-1966.
342	[3]	Baharoon S, Memish ZA. MERS-CoV as an emerging respiratory illness: A
343		review of prevention methods. Travel Med Infect Dis. 2019:101520.
344	[4]	Rabaan AA, Al-Ahmed SH, Haque S, et al. SARS-CoV-2, SARS-CoV, and
345		MERS-COV: A comparative overview. Infez Med. 2020;28(2):174-184.
346	[5]	Review Manger Web (RevMan Web) [computer program]. 2019.
347	[6]	Wang N. How to Conduct a Meta-Analysis of Proportions in R: A
348		Comprehensive Tutorial. 2018.
349	[7]	von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP.
350		The Strengthening the Reporting of Observational Studies in Epidemiology
351		(STROBE) statement: guidelines for reporting observational studies. PLoS
352		Med. 2007;4(10):e296.
353	[8]	Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's
354		tool for assessing risk of bias in randomised trials. 2011;343:d5928.
355	[9]	Yu M, Liu Y, Xu D, Zhang R, Lan L, Xu H. Prediction of the Development of
356		Pulmonary Fibrosis Using Serial Thin-Section CT and Clinical Features in
357		Patients Discharged after Treatment for COVID-19 Pneumonia. Korean J
358		Radiol. 2020;21(6):746-755.
359	[10]	Xu K, Chen Y, Yuan J, et al. Factors associated with prolonged viral RNA
360		shedding in patients with COVID-19. Clin Infect Dis. 2020.
361	[11]	Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized
362		Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.
363		JAMA. 2020.
364	[12]	Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics,
365		Comorbidities, and Outcomes Among 5700 Patients Hospitalized With
366		COVID-19 in the New York City Area. JAMA. 2020.
367	[13]	Ouyang Y, Yin J, Wang W, et al. Down-regulated gene expression spectrum
368		and immune responses changed during the disease progression in COVID-19

369		patients. Clin Infect Dis. 2020.
370	[14]	Myers LC, Parodi SM, Escobar GJ, Liu VX. Characteristics of Hospitalized
371		Adults With COVID-19 in an Integrated Health Care System in California.
372		JAMA. 2020.
373	[15]	Mo P, Xing Y, Xiao Y, et al. Clinical characteristics of refractory COVID-19
374	[]	pneumonia in Wuhan, China. <i>Clin Infect Dis.</i> 2020.
375	[16]	Liu Y, Yang Y, Zhang C, et al. Clinical and biochemical indexes from
376	[10]	2019-nCoV infected patients linked to viral loads and lung injury. <i>Sci China</i>
377		<i>Life Sci.</i> 2020;63(3):364-374.
378	[17]	Lian J, Jin X, Hao S, et al. Analysis of Epidemiological and Clinical features
379	[-,]	in older patients with Corona Virus Disease 2019 (COVID-19) out of Wuhan.
380		Clin Infect Dis. 2020.
381	[18]	Jacobs JP, Stammers AH, St Louis J, et al. Extracorporeal Membrane
382	[10]	Oxygenation in the Treatment of Severe Pulmonary and Cardiac Compromise
383		in COVID-19: Experience with 32 patients. <i>ASAIO J.</i> 2020.
384	[19]	Grein J, Ohmagari N, Shin D, et al. Compassionate Use of Remdesivir for
385	[17]	Patients with Severe Covid-19. N Engl J Med. 2020.
386	[20]	Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in Critically Ill
387	[20]	Patients in the Seattle Region — Case Series. <i>N Engl J Med.</i> 2020.
388	[21]	Huang M, Tang T, Pang P, et al. Treating COVID-19 with Chloroquine. <i>J Mol</i>
389	[21]	<i>Cell Biol.</i> 2020;12(4):322-325.
390	[22]	Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a
391	[]	randomised, double-blind, placebo-controlled, multicentre trial. <i>The Lancet</i> .
392		2020.
393	[23]	Tang W, Cao Z, Han M, et al. hydroxychloroquine in patients with mainly
394	[=0]	mild to moderate coronavirus disease 2019: open label, randomised controlled
395		trial. <i>BMJ</i> . 2020;369:m1849.
396	[24]	Singh S, Chakravarty T, Chen P, et al. Allogeneic cardiosphere-derived cells
397	[]	(CAP-1002) in critically ill COVID-19 patients: compassionate-use case series.
398		Basic Res Cardiol. 2020;115(4):36.
399	[25]	Lian N, Xie H, Lin S, Huang J, Zhao J, Lin Q. Umifenovir treatment is not
400	[]	associated with improved outcomes in patients with coronavirus disease 2019:
401		a retrospective study. <i>Clin Microbiol Infect</i> . 2020.
402	[26]	Hung IF, Lung KC, Tso EY, et al. Triple combination of interferon beta-1b,
403		lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to
404		hospital with COVID-19: an open-label, randomised, phase 2 trial. <i>Lancet</i> .
405		2020.
406	[27]	Hu K, Guan WJ, Bi Y, et al. Efficacy and Safety of Lianhuaqingwen Capsules,
407		a repurposed Chinese Herb, in Patients with Coronavirus disease 2019: A
408		multicenter, prospective, randomized controlled trial. <i>Phytomedicine</i> .
409		2020:153242.
410	[28]	Geleris J, Sun Y, Platt J, et al. Observational Study of Hydroxychloroquine in
411		Hospitalized Patients with Covid-19. <i>N Engl J Med.</i> 2020.
412	[29]	Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as
	r⇒×1	

413		a treatment of COVID-19: results of an open-label non-randomized clinical
414		trial. Int J Antimicrob Agents. 2020:105949.
415	[30]	Deng L, Li C, Zeng Q, et al. Arbidol combined with LPV/r versus LPV/r alone
416		against Corona Virus Disease 2019: A retrospective cohort study. J Infect.
417		2020.
418	[31]	Colaneri M, Bogliolo L, Valsecchi P, et al. Tocilizumab for Treatment of
419		Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19
420		REgistry (SMACORE). Microorganisms. 2020;8(5).
421	[32]	CHEN Jun LD, LIU Li,LIU Ping,XU Qingnian,XIA Lu,LING Yun,HUANG
422		Dan,SONG Shuli,ZHANG Dandan,QIAN Zhiping,LI Tao,SHEN
423		Yinzhong,LU Hongzhou. A pilot study of hydroxychloroquine in treatment of
424		patients with common coronavirus disease-19 (COVID-19). J Zhejiang Univ
425		(<i>Med Sci</i>). 2020;49(1):0-0.
426	[33]	Zheng S, Fan J, Yu F, et al. Viral load dynamics and disease severity in
427		patients infected with SARS-CoV-2 in Zhejiang province, China,
428		January-March 2020: retrospective cohort study. <i>BMJ</i> . 2020;369:m1443.
429	[34]	Zhao XY, Xu XX, Yin HS, et al. Clinical characteristics of patients with 2019
430		coronavirus disease in a non-Wuhan area of Hubei Province, China: a
431		retrospective study. BMC Infect Dis. 2020;20(1):311.
432	[35]	Zhang J, Yu M, Tong S, Liu LY, Tang LV. Predictive factors for disease
433		progression in hospitalized patients with coronavirus disease 2019 in Wuhan,
434		China. J Clin Virol. 2020;127:104392.
435	[36]	Yu Y, Xu D, Fu S, et al. Patients with COVID-19 in 19 ICUs in Wuhan, China:
436		a cross-sectional study. Crit Care. 2020;24(1):219.
437	[37]	Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients
438		with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered,
439		retrospective, observational study. Lancet Respir Med. 2020.
440	[38]	Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir-Ritonavir in Adults
441		Hospitalized with Severe Covid-19. N Engl J Med. 2020.
442	[39]	Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of
443		adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.
444		Lancet. 2020;395(10229):1054-1062.
445	[40]	Xu XW, Wu XX, Jiang XG, et al. Clinical findings in a group of patients
446		infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan,
447		China: retrospective case series. BMJ. 2020;368:m606.
448	[41]	Wu J, Liu J, Zhao X, et al. Clinical Characteristics of Imported Cases of
449		COVID-19 in Jiangsu Province: A Multicenter Descriptive Study. Clin Infect
450		Dis. 2020.
451	[42]	Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory
452		Distress Syndrome and Death in Patients With Coronavirus Disease 2019
453		Pneumonia in Wuhan, China. JAMA Intern Med. 2020.
454	[43]	Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical Features of 69 Cases with
455		Coronavirus Disease 2019 in Wuhan, China. Clin Infect Dis. 2020.
456	[44]	Wang D, Yin Y, Hu C, et al. Clinical course and outcome of 107 patients

vel coronavirus, SARS-CoV-2, discharged from two
ina. <i>Crit Care</i> . 2020;24(1):188.
ahmood NR, Wolfe KK, et al. Characteristics and
With Coronavirus Disease 2019 (COVID-19) Infection
d Canadian Pediatric Intensive Care Units. JAMA
J, Chang D, et al. The Effect of Chloroquine,
and Azithromycin on the Corrected QT Interval in
oV-2 Infection. Circ Arrhythm Electrophysiol. 2020.
, Turla F, et al. Clinical presentation and initial
ill patients with severe acute respiratory syndrome
S-CoV-2) infection in Brescia, Italy. J Crit Care.
P, et al. Clinical Characteristics of COVID-19 Patients
oms in Hubei, China: A Descriptive, Cross-Sectional,
J Gastroenterol. 2020;115(5):766-773.
g HH, et al. Evaluation of SARS-CoV-2 RNA shedding
s and clinical characteristics of 10 patients with
Int J Biol Sci. 2020;16(10):1698-1707.
g L, et al. Analysis of factors associated with disease
ed patients with 2019 novel coronavirus disease. Chin
32-1038.
g Y, et al. Clinical characteristics of novel coronavirus
hospitals in Hubei Province. Chin Med J.
0.000000000000744.
C, et al. Clinical characteristics of 60 discharged cases of
as-infected pneumonia in Taizhou, China. Ann Transl
X, et al. Clinical features of patients infected with 2019
X, et al. Clinical features of patients infected with 2019 Juhan, China. <i>Lancet</i> . 2020;395(10223):497-506.
*
Yuhan, China. <i>Lancet</i> . 2020;395(10223):497-506. t al. Risk Factors Associated with Clinical Outcomes in
Vuhan, China. Lancet. 2020;395(10223):497-506.
Yuhan, China. <i>Lancet</i> . 2020;395(10223):497-506. t al. Risk Factors Associated with Clinical Outcomes in alized Patients in Wuhan, China. <i>Clin Infect Dis</i> . 2020.
Yuhan, China. <i>Lancet</i> . 2020;395(10223):497-506. t al. Risk Factors Associated with Clinical Outcomes in alized Patients in Wuhan, China. <i>Clin Infect Dis</i> . 2020. hung JH, et al. Clinical Features and Outcomes of 98
Vuhan, China. <i>Lancet</i> . 2020;395(10223):497-506. t al. Risk Factors Associated with Clinical Outcomes in alized Patients in Wuhan, China. <i>Clin Infect Dis</i> . 2020. hung JH, et al. Clinical Features and Outcomes of 98 with SARS-CoV-2 Infection in Daegu, South Korea: A y. <i>Yonsei Med J</i> . 2020;61(5):431-437.
Yuhan, China. <i>Lancet</i> . 2020;395(10223):497-506. t al. Risk Factors Associated with Clinical Outcomes in alized Patients in Wuhan, China. <i>Clin Infect Dis</i> . 2020. hung JH, et al. Clinical Features and Outcomes of 98 with SARS-CoV-2 Infection in Daegu, South Korea: A
Yuhan, China. <i>Lancet</i> . 2020;395(10223):497-506. t al. Risk Factors Associated with Clinical Outcomes in alized Patients in Wuhan, China. <i>Clin Infect Dis</i> . 2020. hung JH, et al. Clinical Features and Outcomes of 98 with SARS-CoV-2 Infection in Daegu, South Korea: A <i>y. Yonsei Med J.</i> 2020;61(5):431-437. ng X, et al. Epidemiological and clinical characteristics
Yuhan, China. <i>Lancet</i> . 2020;395(10223):497-506. t al. Risk Factors Associated with Clinical Outcomes in alized Patients in Wuhan, China. <i>Clin Infect Dis</i> . 2020. hung JH, et al. Clinical Features and Outcomes of 98 with SARS-CoV-2 Infection in Daegu, South Korea: A <i>y. Yonsei Med J.</i> 2020;61(5):431-437. ng X, et al. Epidemiological and clinical characteristics novel coronavirus pneumonia in Wuhan, China: a <i>tet.</i> 2020;395(10223):507-513.
 Vuhan, China. Lancet. 2020;395(10223):497-506. t al. Risk Factors Associated with Clinical Outcomes in alized Patients in Wuhan, China. Clin Infect Dis. 2020. hung JH, et al. Clinical Features and Outcomes of 98 with SARS-CoV-2 Infection in Daegu, South Korea: A y. Yonsei Med J. 2020;61(5):431-437. ng X, et al. Epidemiological and clinical characteristics novel coronavirus pneumonia in Wuhan, China: a et. 2020;395(10223):507-513. C, et al. Clinical characteristics and intrauterine vertical
Yuhan, China. <i>Lancet</i> . 2020;395(10223):497-506. t al. Risk Factors Associated with Clinical Outcomes in alized Patients in Wuhan, China. <i>Clin Infect Dis</i> . 2020. hung JH, et al. Clinical Features and Outcomes of 98 with SARS-CoV-2 Infection in Daegu, South Korea: A <i>y. Yonsei Med J.</i> 2020;61(5):431-437. ng X, et al. Epidemiological and clinical characteristics novel coronavirus pneumonia in Wuhan, China: a <i>tet.</i> 2020;395(10223):507-513.
 Vuhan, China. Lancet. 2020;395(10223):497-506. t al. Risk Factors Associated with Clinical Outcomes in alized Patients in Wuhan, China. Clin Infect Dis. 2020. hung JH, et al. Clinical Features and Outcomes of 98 with SARS-CoV-2 Infection in Daegu, South Korea: A y. Yonsei Med J. 2020;61(5):431-437. ng X, et al. Epidemiological and clinical characteristics novel coronavirus pneumonia in Wuhan, China: a et. 2020;395(10223):507-513. C, et al. Clinical characteristics and intrauterine vertical of COVID-19 infection in nine pregnant women: a w of medical records. The Lancet.
 Vuhan, China. Lancet. 2020;395(10223):497-506. t al. Risk Factors Associated with Clinical Outcomes in alized Patients in Wuhan, China. Clin Infect Dis. 2020. hung JH, et al. Clinical Features and Outcomes of 98 with SARS-CoV-2 Infection in Daegu, South Korea: A y. Yonsei Med J. 2020;61(5):431-437. ng X, et al. Epidemiological and clinical characteristics novel coronavirus pneumonia in Wuhan, China: a eet. 2020;395(10223):507-513. C, et al. Clinical characteristics and intrauterine vertical of COVID-19 infection in nine pregnant women: a

501		2020.
502	[59]	Cai J, Xu J, Lin D, et al. A Case Series of children with 2019 novel
503	[0]]	coronavirus infection: clinical and epidemiological features. <i>Clinical</i>
504		infectious diseases : an official publication of the Infectious Diseases Society
505		of America. 2020:ciaa198.
506	[60]	Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of
507		Covid-19 - Preliminary Report. N Engl J Med. 2020.
508	[61]	Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G. Graphical tools
509		for network meta-analysis in STATA. PLoS One. 2013;8(10):e76654.
510	[62]	Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features,
511		evaluation and treatment coronavirus (COVID-19). In: Statpearls [internet].
512		StatPearls Publishing; 2020.
513	[63]	Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease
514		2019 in China. N Engl J Med. 2020;382(18):1708-1720.
515	[64]	Saghazadeh A, Rezaei N. Towards treatment planning of COVID-19:
516		Rationale and hypothesis for the use of multiple immunosuppressive agents:
517		Anti-antibodies, immunoglobulins, and corticosteroids. Int Immunopharmacol.
518		2020;84:106560.
519	[65]	Cortegiani A, Ippolito M, Ingoglia G, Einav S. Chloroquine for COVID-19:
520		rationale, facts, hopes. Critical Care. 2020;24(1):210.
521		
522		
523		
524		
525		
526		
520		
527		
52,		
528		
529		
530		
531		
532		

533	
534	
535	
526	
536	
537	
538	
539	
540	Tables
541	Table 1. Summary of the impact of the eight treatments on COVID-19 severity.
542	Figures
543	Figure 1. PRISMA 2009 flow diagram.
544	Figure 2. Proportional meta-analysis forest plots of the eight treatment strategies for
545	COVID-19 by the random-effect model. Cases, number of patients taking the drug;
546	Total, the total number of patients enrolled in the study.
547	Figure 3. a) Network frequentist model of 10 treatment approaches for COVID-19
548	and b) the mean difference between each treatment and placebo. The edge thickness is
549	proportional to the comparison frequency of both treatments, represented by the nodes
550	the edge connects. These results were obtained by the random-effect model.
551	Figure 4. The matrix for the effect sizes of all possible treatment combinations. The
552	risk ratios and their 95% confidence intervals are shown generated by the
553	random-effect model.
554	
555	Supplemental Content
556	Supplemental Content 1. PRISMA 2009 Checklist.
557	Supplemental Content 2. Characteristics of the 52 studies included in the
558	meta-analysis.

21

559 Supplemental Content 3. Characteristics of the studies included in the proportional

560 meta-analysis.

- 561 Supplemental Content 4. Heterogeneity results from the proportional meta-analysis.
- 562 Supplemental Content 5. A summary of the 13 studies included in the network
- 563 meta-analysis.
- 564 Supplemental Content 6. Cochrane Risk of bias analysis (ROB-2) of five randomized
- trial studies of COVID-19 treatment.
- 566 Supplemental Content 7. Subgroup meta-analysis of six treatments to estimate the
- impact of each treatment on the severity of COVID-19. The forest plots showing the
- treatment effect on different subgroups (severe versus non-severe, ICU versus
- non-ICU, death versus survival, and deterioration versus discharge) by the
- 570 Mantel-Haenszel random-effect model using REVMAN 5 software.
- 571 Supplemental Content 8. meta-regression plots showing the impact of chloroquine or
- 572 hydroxychloroquine and tocilizumab on the severity of COVID-19. The
- 573 meta-regression plots showing the treatment effect (log (risk ratio)) versus the number
- of patients who died or stayed in ICU obtained by the mixed-effect model.
- 575 Supplemental Content 9. Forest plots showing outlying and influential studies in eight
- treatments by externally studentized residuals analysis. Each box represents a
- summary proportion estimated by the leave-one-out study, and the dashed reference
- 578 line indicates where the original summary proportion lies. The further a box deviates
- from the reference line; the more pronounced the impact of the corresponding
- leaving-out study exerts on the original summary proportion.
- 581 Supplemental Content 10. Diagnostic plots showing significant and influential studies
- 582 by analyses of externally studentized residuals, difference in fits values, Cook's
- distances, covariance ratios, tau2, and Q-test of leave-one-out heterogeneity, hat
- values, and weights.
- 585 Supplemental Content 11. Funnel plots showing proportional meta-analysis
- publication bias by testing for the funnel plot asymmetry using the Egger's regression
- 587 test. The Z and P values are shown.

- 588 Supplemental Content 12. Dot plot showing the treatment ranking by the network
- 589 meta-analysis. The ranking is based on P scores determined by the point estimates and
- standard errors of the network meta-analysis.
- 591 Supplemental Content 13. Comparison-adjusted funnel plot showing the network
- 592 meta-analysis publication bias by testing for the funnel plot asymmetry using the
- 593 Egger's regression test.

594

595

596

Treatment	Pooled effect size	<i>P</i> -value	Method	Heterogeneity <i>I</i> ² (%)
Glucocorticoids	Risk ratio (RR) = 2.01, 95% CI: [1.48, 2.74]	< 0.0001	Subgroup meta-analysis ^c	87
Antibiotics	RR = 1.03, 95% CI: [0.99, 1.08]	0.16	Subgroup meta-analysis	45
Antivirals	RR = 1.00, 95% CI: [0.99, 1.01]	0.93	Subgroup meta-analysis	0
Immunoglobulins	RR = 3.09, 95% CI: [1.63, 5.87]	0.0005	Subgroup meta-analysis	82
Renal replacement therapy	RR = 10.95, 95% CI: [0.46, 258.94]	0.14	Subgroup meta-analysis	99
Interferons	RR = 1.12, 95% CI: [0.54, 2.30]	0.77	Subgroup meta-analysis	48
Chloroquine or hydroxychloroquine ^a	F = 0.033	0.85	Meta-regression	97.27
Chloroquine or hydroxychloroquine ^b	F = 0.03	0.87	Meta-regression	97.27
Tocilizumab ^{<i>a</i>}	F = 25.53	0.02	Meta-regression	26.47
Tocilizumab ^b	F = 19.37	0.02	Meta-regression	26.47

597 Table 1. Summary of the impact of the eight treatments on COVID-19 severity

598 note:

^{*a*} The moderator used in the meta-regression is the number of patients in ICU.

600 ^b The moderator used in the meta-regression is the number of patients died.

601 ^c Subgroup meta-analysis of severe versus non-severe, ICU versus non-ICU, death versus survival, and


602 deterioration versus discharge by the random-effect model.

^d Meta-regression of two moderators (the number of patients in ICU and the number of patients died)


604 by the mixed-effect model.

605

606



Antibiotics



Study	Cases	Total	Prevalence	e 95% CI	
Lei Pan	184	204	0.90	[0.85, 0.94]	
Yongpo Jiang	60	60	1.00	[0.94, 1.00]	
Xin-Ying Zhao	81	91	0.89	[0.81, 0.95]	
Wei Tang	95	150	0.63	[0.55, 0.71]	
Xiao-Wei Xu	55	62	0.89	[0.78, 0.95]	
Shufa Zheng	96	96	1.00	[0.96, 1.00]	
Kui Liu	105	137	0.77	[0.69, 0.83]	_
Jianlei Cao	100	102	0.98	[0.93, 1.00]	
Ling Hu	230	323	0.71	[0.66, 0.76]	
Jiangshan Lian	668	788	0.85	[0.82, 0.87]	
Pingzheng Mo	45	155	0.29	[0.22, 0.37]	
Yabo Ouyang	7	11	0.64	[0.31, 0.89]	
Zhongliang Wang	66	67	0.99	[0.92, 1.00]	
Jian Wu	80	80	1.00	[0.95, 1.00]	
Kaijin Xu	19	113	0.17	[0.10, 0.25]	
Ningfang Lian	45	81	0.56	[0.44, 0.67]	
Cai Jiehao	5	10	0.50	[0.19, 0.81]	
Dawei Wang	105	107	0.98	[0.93, 1.00]	_
Yuan Yu	117	226	0.52	[0.45, 0.58]	
lek Long Lo	10	10	1.00	[0.69, 1.00]	-
Jun Zhang	111	111	1.00	[0.97, 1.00]	
Simone Piva	27	33	0.82	[0.65, 0.93]	
Lisi Deng	17	33	0.52	[0.34, 0.69]	
Mingxing Huang	12	22	0.55	[0.32, 0.76]	
CHEN Jun	24	30	0.80	[0.61, 0.92]	
Myers	166	377	0.44	[0.39, 0.49]	-
Dawei Wang	124	138	0.90	[0.84, 0.94]	
Chaomin Wu	170	201	0.85	[0.79, 0.89]	_
Lara S. Shekerdemiar		48	0.17	[0.07, 0.30]	-
Minhua Yu	32	32	1.00	[0.89, 1.00]	_
Huijun Chen	6	9	0.67	[0.30, 0.93]	
Nanshan Chen	75	99	0.76	[0.66, 0.84]	
Chaolin Huang	38	41	0.93	[0.80, 0.98]	_
Yeming Wang	158	236	0.67	[0.61, 0.73]	_ -
Fei Zhou	41	191	0.21	[0.16, 0.28]	
Xiaobo Yang	23	52	0.44	[0.30, 0.59]	
Marta Colaneri	21	112	0.19	[0.12, 0.27]	
J. Grein, N	36	53	0.68	[0.54, 0.80]	
Ke Hu	242	284	0.85	[0.81, 0.89]	
Yingxia Liu	12	12	1.00	[0.74, 1.00]	
Kyung Soo Hong	97	98	0.99	[0.94, 1.00]	_
JEFFREY P. JACOBS		32	0.09	[0.02, 0.25]	-
Wei Liu Ravan K. Bhatraiu	45 7	78 24	0.58	[0.46, 0.69]	




-8

- 10


- 10


-




medRxiv preprint doi: https://doi.org/10.1101/2020.08.24.20180638; this version posted August 25, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who fies the field metal wave lice as the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . 0.2 0.4 0.6 0.8 1 0.2 0.4 0.6 0.8

Rer	nal re	plce	ment the	rapy	
Study	Cases	Total	Prevalence	95% CI	
Xin-Ying Zhao Cai Jiehao	3 6	91 102	0.03 0.06	[0.01, 0.09]	
Ling Hu	72	323	0.00	[0.02, 0.12]	
Yuan Yu	24	226	0.11	[0.07, 0.15]	
Simone Piva	2	33	0.06	[0.01, 0.20]	
Safiya Richardson	81	2634	0.03	[0.02, 0.04]	• • • • • • • • • • • • • • • • • • •
Nanshan Chen	9	99	0.09	[0.04, 0.17]	
Chaolin Huang	3	41	0.07	[0.02, 0.20]	
Yeming Wang	6	236	0.03	[0.01, 0.05]	
Fei Zhou	10	191	0.05	[0.03, 0.09]	
Xiaobo Yang	9	52	0.17	[0.08, 0.30]	
Cao.B	9	199	0.05	[0.02, 0.08]	
Kyung Soo Hong	3	98	0.03	[0.01, 0.09]	
Dawei Wang	2	138	0.01	[0.00, 0.05]	
$I^2 = 98\%, P < 0.01$	Sun	nmary	0.06	[0.04, 0.09]	0.05 0.1 0.15 0.2 0.25 0.3
					0.00 0.1 0.10 0.2 0.20 0.0






Immunoglobulins



Tocilizumab




Antivirals

Glucocorticoids

95% CI

[0.32, 0.46]

[0.07, 0.27]



а

b

Arbidol + lopinavir/ritonavir									
1.50 [0.34, 6.61]	CAP-1002								
1.64 [0.52, 5.20]	1.10 [0.26, 4.57]	Chloroquine							
1.30 [0.39, 4.35]	0.87 [0.30, 2.49]	0.79 [0.26, 2.47]	Hydroxychloroquine						
1.53 [0.40, 5.88]	1.02 [0.30, 3.42]	0.93 [0.26, 3.37]	1.17 [0.50, 2.72]	Lianhuaqingwen					
1.77 [0.75, 4.20]	1.18 [0.35, 3.95]	1.08 [0.50, 2.32]	1.36 [0.59, 3.14]	1.16 [0.41, 3.26]	Lopinavir/ritonavir				
1.72 [0.55, 5.32]	1.15 [0.28, 4.70]	1.05 [0.36, 3.01]	1.32 [0.43, 4.01]	1.12 [0.32, 3.98]	0.97 [0.47, 2.01]	Lopinavir/ritonavir + interferon			
1.70 [0.55, 5.26]	1.13 [0.43, 2.97]	1.03 [0.36, 2.97]	1.30 [0.86, 1.98]	1.11 [0.53, 2.31]	0.96 [0.46, 1.99]	0.99 [0.35, 2.77]	Placebo		
1.38 [0.40, 4.80]	0.92 [0.31, 2.76]	0.84 [0.26, 2.74]	1.06 [0.54, 2.07]	0.91 [0.37, 2.22]	0.78 [0.32, 1.91]	0.81 [0.25, 2.56]	0.81 [0.48, 1.37]	Remdesivir	
1.80 [0.46, 7.06]	1.20 [0.35, 4.12]	1.10 [0.30, 4.05]	1.38 [0.58, 3.31]	1.18 [0.41, 3.41]	1.02 [0.35, 2.93]	1.05 [0.29, 3.79]	1.06 [0.49, 2.29]	1.30 [0.51, 3.29]	Umifenovir

-
